Insilico Medicine

What the company is

Insilico Medicine is a drug discovery company founded in the United States in 2014^[1]. It describes its model as a dual engine: one engine is AI algorithm development, the other is in-house drug development^[1]. In practice that means the company both sells software to other drugmakers and uses computational methods to build its own portfolio of drug candidates.

The Pharma.AI platform

Its main software product is Pharma.AI, a platform that spans biology, generative chemistry, clinical development and scientific research^[1]. Those four areas map onto stages of early drug discovery: picking a biological target worth attacking, designing molecules that act on it, planning and running clinical studies, and supporting research work around them. "Generative" here means the software proposes chemical structures rather than only screening lists of existing compounds.

Since 2020 the platform has been sold as a modular software suite, so a customer can license individual parts instead of the whole system^[1]. The company says it holds licensing deals with 13 of the world's 20 largest pharmaceutical companies^[1].

Automation in the laboratory

The company built an automated biology laboratory called Life Star 1, which began operation in December 2022, and upgraded it as Life Star 2 in September 2025^[1]. Automated labs matter for this kind of work because machine learning models need large amounts of experimental data, and robots running experiments around the clock can generate it faster and more consistently than bench work alone, while also testing the model's predictions against real results.

Pipeline and the speed claim

Between 2021 and 2024, across more than 20 in-house programmes, the company says it reduced the time from programme start to preclinical candidate nomination to 12 to 18 months, against a traditional average of 4.5 years^[1]. Preclinical candidate nomination is the point at which a project settles on the molecule it will take through safety studies and toward first-in-human testing, so shortening that step compresses the front end of drug development.

It reports more than 30 programmes across fibrosis, oncology, immunology, inflammation, cardiometabolics and central nervous system disease^[1]. Ten of those programmes have received IND clearance and seven are in active clinical development^[1]. IND clearance is regulatory permission to begin testing a candidate in people, which marks the transition from laboratory work to clinical trials.

The company's pipeline page gives a larger count: more than 40 programmes in total and 35 preclinical candidates nominated since 2021^[2]. The two figures come from different company materials and do not match exactly.

Partnerships

The company has struck three out-licensing deals, including with Exelixis and Menarini, with a maximum total value of up to $2.1 billion^[1]. Out-licensing means handing a programme to a partner, which then carries development forward, in exchange for payments that typically depend on milestones. It also has co-development partnerships with Fosun Pharma, Sanofi and Lilly, where both sides share the work rather than one buying the asset outright^[1].

On the software side, the modular suite sold since 2020 gives large pharmaceutical companies a way to try individual pieces of Pharma.AI without committing to the whole platform^[1].

The team

As of the listing, the R&D team numbered 249 scientists, with master's and doctoral degree holders making up 87 percent^[1].

Where it sits

The pitch behind AI drug discovery is that software can narrow the enormous space of possible molecules and biological targets faster and more cheaply than exhaustive experiment. Insilico's version of that pitch combines three things: a platform sold as a product, a pipeline of its own programmes, and an automated laboratory generating data. The publicly checkable results so far are counts — programmes, nominated candidates, IND clearances, partnership deals — and reported timelines. Whether those timelines translate into medicines that work in patients is decided in clinical trials, which is where seven of the company's programmes currently sit^[1].

^[1]: Insilico Medicine, "Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO". ^[2]: Insilico Medicine, "Pipeline - Insilico Medicine".